0000897078 false --12-31 Q3 P3Y 0000897078 2022-01-01 2022-09-30 0000897078 2022-11-15 0000897078 2022-09-30 0000897078 2021-12-31 0000897078 us-gaap:SeriesCPreferredStockMember 2022-09-30 0000897078 us-gaap:SeriesCPreferredStockMember 2021-12-31 0000897078 2021-01-01 2021-09-30 0000897078 2022-07-01 2022-09-30 0000897078 2021-07-01 2021-09-30 0000897078 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000897078 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-12-31 0000897078 us-gaap:CommonStockMember 2021-12-31 0000897078 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000897078 KOAN:SubscriptionReceivableMember 2021-12-31 0000897078 us-gaap:RetainedEarningsMember 2021-12-31 0000897078 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0000897078 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-03-31 0000897078 us-gaap:CommonStockMember 2022-03-31 0000897078 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000897078 KOAN:SubscriptionReceivableMember 2022-03-31 0000897078 us-gaap:RetainedEarningsMember 2022-03-31 0000897078 2022-03-31 0000897078 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0000897078 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-06-30 0000897078 us-gaap:CommonStockMember 2022-06-30 0000897078 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000897078 KOAN:SubscriptionReceivableMember 2022-06-30 0000897078 us-gaap:RetainedEarningsMember 2022-06-30 0000897078 2022-06-30 0000897078 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0000897078 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2020-12-31 0000897078 us-gaap:CommonStockMember 2020-12-31 0000897078 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000897078 KOAN:SubscriptionReceivableMember 2020-12-31 0000897078 us-gaap:RetainedEarningsMember 2020-12-31 0000897078 2020-12-31 0000897078 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-03-31 0000897078 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-03-31 0000897078 us-gaap:CommonStockMember 2021-03-31 0000897078 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000897078 KOAN:SubscriptionReceivableMember 2021-03-31 0000897078 us-gaap:RetainedEarningsMember 2021-03-31 0000897078 2021-03-31 0000897078 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0000897078 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-06-30 0000897078 us-gaap:CommonStockMember 2021-06-30 0000897078 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000897078 KOAN:SubscriptionReceivableMember 2021-06-30 0000897078 us-gaap:RetainedEarningsMember 2021-06-30 0000897078 2021-06-30 0000897078 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0000897078 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-01-01 2022-03-31 0000897078 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000897078 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000897078 KOAN:SubscriptionReceivableMember 2022-01-01 2022-03-31 0000897078 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000897078 2022-01-01 2022-03-31 0000897078 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0000897078 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-04-01 2022-06-30 0000897078 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000897078 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000897078 KOAN:SubscriptionReceivableMember 2022-04-01 2022-06-30 0000897078 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000897078 2022-04-01 2022-06-30 0000897078 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0000897078 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-07-01 2022-09-30 0000897078 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000897078 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000897078 KOAN:SubscriptionReceivableMember 2022-07-01 2022-09-30 0000897078 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000897078 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0000897078 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-03-31 0000897078 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000897078 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000897078 KOAN:SubscriptionReceivableMember 2021-01-01 2021-03-31 0000897078 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000897078 2021-01-01 2021-03-31 0000897078 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0000897078 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-04-01 2021-06-30 0000897078 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000897078 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000897078 KOAN:SubscriptionReceivableMember 2021-04-01 2021-06-30 0000897078 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000897078 2021-04-01 2021-06-30 0000897078 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0000897078 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-07-01 2021-09-30 0000897078 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000897078 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000897078 KOAN:SubscriptionReceivableMember 2021-07-01 2021-09-30 0000897078 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000897078 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-09-30 0000897078 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-09-30 0000897078 us-gaap:CommonStockMember 2022-09-30 0000897078 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000897078 KOAN:SubscriptionReceivableMember 2022-09-30 0000897078 us-gaap:RetainedEarningsMember 2022-09-30 0000897078 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0000897078 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-09-30 0000897078 us-gaap:CommonStockMember 2021-09-30 0000897078 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000897078 KOAN:SubscriptionReceivableMember 2021-09-30 0000897078 us-gaap:RetainedEarningsMember 2021-09-30 0000897078 2021-09-30 0000897078 KOAN:AsefiGroupMember KOAN:SeparationAndReleaseAgreementMember 2020-05-21 2020-05-22 0000897078 KOAN:MrSelzerMember KOAN:VotingAgreementMember us-gaap:SeriesCPreferredStockMember KOAN:AsefiGroupMember 2020-05-21 2020-05-22 0000897078 KOAN:AsefiGroupMember 2020-07-19 2020-07-20 0000897078 KOAN:AsefiGroupMember 2020-07-20 0000897078 srt:MinimumMember 2022-01-01 2022-09-30 0000897078 srt:MaximumMember 2022-01-01 2022-09-30 0000897078 us-gaap:FairValueInputsLevel1Member 2022-09-30 0000897078 us-gaap:FairValueInputsLevel2Member 2022-09-30 0000897078 us-gaap:FairValueInputsLevel3Member 2022-09-30 0000897078 us-gaap:FairValueInputsLevel1Member 2021-12-31 0000897078 us-gaap:FairValueInputsLevel2Member 2021-12-31 0000897078 us-gaap:FairValueInputsLevel3Member 2021-12-31 0000897078 us-gaap:SeriesAPreferredStockMember 2020-05-21 2020-05-22 0000897078 us-gaap:SeriesCPreferredStockMember 2020-05-21 2020-05-22 0000897078 KOAN:SeparationAndReleaseAgreementMember KOAN:GeoffreySelzerMember 2020-05-21 2020-05-22 0000897078 KOAN:GeoffreySelzerMember KOAN:TransactionOneMember 2020-05-21 2020-05-22 0000897078 KOAN:GeoffreySelzerMember KOAN:TransactionTwoMember 2020-05-21 2020-05-22 0000897078 KOAN:GeoffreySelzerMember KOAN:TransactionThreeMember 2020-05-21 2020-05-22 0000897078 KOAN:GeoffreySelzerMember KOAN:TransactionFourMember 2020-05-21 2020-05-22 0000897078 KOAN:GeoffreySelzerMember KOAN:TransactionFiveMember 2020-05-21 2020-05-22 0000897078 KOAN:GeoffreySelzerMember KOAN:TransactionSixMember 2020-05-21 2020-05-22 0000897078 KOAN:GeoffreySelzerMember KOAN:TransactionSevenMember 2020-05-21 2020-05-22 0000897078 KOAN:GeoffreySelzerMember KOAN:TransactionEightMember 2020-05-21 2020-05-22 0000897078 KOAN:SeparationAndReleaseAgreementMember KOAN:WaisAsefiMember srt:MaximumMember 2021-05-12 2021-05-13 0000897078 srt:MinimumMember KOAN:WaisAsefiMember KOAN:SeparationAndReleaseAgreementMember 2021-05-12 2021-05-13 0000897078 KOAN:SeparationAndReleaseAgreementMember KOAN:WaisAsefiMember 2021-05-12 2021-05-14 0000897078 KOAN:SeparationAndReleaseAgreementMember KOAN:WaisAsefiMember 2021-06-26 2021-06-27 0000897078 KOAN:SeparationAndReleaseAgreementMember KOAN:WaisAsefiMember 2021-08-10 2021-08-11 0000897078 srt:ChiefExecutiveOfficerMember 2022-09-30 0000897078 srt:ChiefExecutiveOfficerMember 2021-12-31 0000897078 KOAN:ConvertiblePromissoryNoteMember us-gaap:UnsecuredDebtMember 2022-09-30 0000897078 KOAN:ConvertiblePromissoryNoteMember us-gaap:UnsecuredDebtMember 2022-01-01 2022-09-30 0000897078 2022-01-01 2022-01-02 0000897078 2022-01-02 0000897078 KOAN:InvestorsMember KOAN:SecuritiesPurchaseAgreementsMember KOAN:ConvertiblePromissoryNotesOneMember 2022-01-28 0000897078 KOAN:InvestorsMember KOAN:SecuritiesPurchaseAgreementsMember KOAN:ConvertiblePromissoryNotesTwoMember 2022-01-28 0000897078 KOAN:InvestorsMember KOAN:SecuritiesPurchaseAgreementsMember KOAN:ConvertiblePromissoryNotesMember 2022-01-27 2022-01-28 0000897078 KOAN:SecuritiesPurchaseAgreementMember KOAN:ConvertiblePromissoryNotesMember KOAN:InvestorsMember srt:MaximumMember 2022-01-28 0000897078 KOAN:SecuritiesPurchaseAgreementsMember KOAN:ConvertiblePromissoryNotesMember 2022-02-04 0000897078 KOAN:SecuritiesPurchaseAgreementsMember KOAN:ConvertiblePromissoryNotesMember 2022-02-03 2022-02-04 0000897078 KOAN:SecuritiesPurchaseAgreementsMember KOAN:ConvertiblePromissoryNotesMember KOAN:InvestorsMember 2022-03-03 0000897078 KOAN:SecuritiesPurchaseAgreementsMember KOAN:ConvertiblePromissoryNotesMember KOAN:InvestorsMember 2022-03-02 2022-03-03 0000897078 KOAN:SecuritiesPurchaseAgreementsMember KOAN:ConvertiblePromissoryNotesMember 2022-09-30 0000897078 KOAN:ConvertiblePromissoryNotesMember 2022-03-03 0000897078 KOAN:ConvertiblePromissoryNotesMember 2022-03-02 2022-03-03 0000897078 2022-03-02 2022-03-03 0000897078 us-gaap:InvestorMember 2022-03-02 2022-03-03 0000897078 us-gaap:InvestorMember 2022-03-03 0000897078 KOAN:InvestorsMember KOAN:SecuritiesPurchaseAgreementsMember KOAN:ConvertiblePromissoryNotesOneMember 2022-06-27 0000897078 KOAN:InvestorsMember KOAN:SecuritiesPurchaseAgreementsMember KOAN:ConvertiblePromissoryNotesMember 2022-06-25 2022-06-27 0000897078 KOAN:ConvertiblePromissoryNoteMember KOAN:AJBCapitalInvestmentsLLCMember 2022-08-08 0000897078 KOAN:ConvertiblePrommissoryNoteMember KOAN:AJBCapitalInvestmentsLLCMember 2022-08-08 0000897078 KOAN:ConvertiblePrommissoryNoteMember KOAN:AJBCapitalInvestmentsLLCMember 2022-08-08 2022-08-08 0000897078 KOAN:InvestorsMember 2022-08-08 2022-08-08 0000897078 2022-08-08 2022-08-08 0000897078 KOAN:ConvertiblePromissoryNoteMember 2022-01-01 2022-09-30 0000897078 KOAN:ConvertiblePromissoryNoteMember 2021-01-01 2021-09-30 0000897078 2019-10-15 2019-10-16 0000897078 KOAN:EmploymentAgreementsMember KOAN:GeoffreySelzerMember 2019-10-24 2019-10-25 0000897078 KOAN:EmploymentAgreementsMember KOAN:PamelaKerwinMember 2019-10-24 2019-10-25 0000897078 KOAN:EmploymentAgreementsMember KOAN:DavidThielenMember 2019-10-24 2019-10-25 0000897078 KOAN:EmploymentAgreementsMember 2019-10-24 2019-10-25 0000897078 us-gaap:CommonStockMember KOAN:VendorMember 2022-07-01 2022-09-30 0000897078 KOAN:VendorsMember 2022-01-01 2022-09-30 0000897078 2020-04-01 2020-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

  ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the quarterly period ended September 30, 2022

 

  ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934

 

For the transition period from __________ to__________

 

Commission File Number: 000-21202

 

Resonate Blends, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   58-1588291

(State or other jurisdiction

of incorporation or organization)

  

(IRS Employer

Identification No.)

 

26565 Agoura Road, Suite 200

Calabasas, CA 91302

(Address of principal executive offices)

 

571-888-0009

(Registrant’s telephone number)

 

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

☒ Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.

 

  ☐ Large accelerated filer ☐ Accelerated filer
  ☒ Non-accelerated filer ☒ Smaller reporting company
    ☐ Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

 

Securities registered pursuant to Section 12(b) of the Act: None

 

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 75,412,604 common shares as of November 15, 2022

 

 

 

 

 

 

https:||www.sec.gov|Archives|edgar|data|897078|000149315222023730|form10-q_001.jpg

 

TABLE OF CONTENTS

 

    Page
PART I – FINANCIAL INFORMATION  
     
Item 1: Financial Statements  
Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations 3
Item 3: Quantitative and Qualitative Disclosures About Market Risk 8
Item 4: Controls and Procedures 8
     
PART II – OTHER INFORMATION 10
     
Item 1: Legal Proceedings 10
Item 1A: Risk Factors 10
Item 2: Unregistered Sales of Equity Securities and Use of Proceeds 10
Item 3: Defaults Upon Senior Securities 10
Item 4: Mine Safety Disclosures 10
Item 5: Other Information 10
Item 6: Exhibits 10

 

2

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

Our consolidated financial statements included in this Form 10-Q are as follows:

 

  F-1 Consolidated Balance Sheets as of September 30, 2022 (unaudited) and December 31, 2021;
  F-2 Consolidated Statements of Operations for the three and nine months period ended September 30, 2022 and 2021 (unaudited);
  F-3 Consolidated Statement of Stockholders’ Equity (Deficit) for the nine months period ended September 30, 2022 (unaudited);
  F-4 Consolidated Statements of Cash Flows for the nine months period ended September 30, 2022 and 2021 (unaudited); and
  F-5 Notes to Consolidated Financial Statements.

 

These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10-Q. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim nine months period ended September 30, 2022 are not necessarily indicative of the results that can be expected for the full year.

 

 

 

 

RESONATE BLENDS, INC.

Consolidated Balance Sheets

As of September 30, 2022 (unaudited) and December 31, 2021

 

         
   September 30,2022   December 31, 2021 
ASSETS          
Current assets          
Cash and cash equivalents  $274,840   $12,913 
Advances to Suppliers   19,592    10,830 
Other receivable   126,811    - 
Inventories   195,288    245,776 
Total current assets   616,531    269,519 
Fixed assets, net   24,824    31,337 
Derivative Valuation allowance   -    - 
Investment in equity method investee   100    100 
TOTAL ASSETS   641,455    300,956 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
Current liabilities          
Accounts payable and accrued liabilities   314,843    206,873 
Due to related parties   43,000    45,000 
Convertible notes payable, net of discount   988,800    1,865,000 
Derivative liability   72,487    2,286,014 
Settlement liability          
Current liabilities of discontinued operations        - 
Total current liabilities   1,419,130    4,402,887 
Total liabilities   1,419,130    4,402,887 
Stockholders’ deficit          
Preferred stock, 10,000,000 shares authorized, $0.0001 par value, 0 shares issued.          
Series C - Preferred stock, 2,000,000 shares authorized, $0.0001 par value, 2,000,000 issued and outstanding   200    200 
Common stock; $0.0001 par value; 200,000,000 shares authorized; 75,412,604 and 45,046,637 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively.   7,541    4,504 
Stock subscription receivable   (261,059)   

-

 
Additional paid-in capital   24,685,822    21,867,416 
Accumulated deficit   (25,210,179)   (25,974,051)
Total Stockholders’ deficit   (777,675)   (4,101,931)
TOTAL LIABILITIES AND STOCKHOLDER’S EQUITY  $641,455   $300,956 

 

The accompanying notes are an integral part of these audited consolidated financial statements

 

F-1

 

 

RESONATE BLENDS, INC.

Consolidated Statements of Operations

For the three and nine months ended September 30, 2022 and 2021

(unaudited)

 

                 
   Nine Months Ended   Three Months Ended 
   September 30 2022   September 30 2021   September 30 2022   September 30 2021 
REVENUES  $40,917   $7,574   $10,429    7,574 
COST OF REVENUES   24,996    12,304    9,718    12,304 
Gross profit   15,921    (4,730)   711    (4,730)
Operating expenses                    
Advertising   330,255    435,212    94,978    224,294 
General and administrative expenses   138,373    84,518    39,083    (31,634)
Legal and Professional fees   136,307    517,925    62,969    90,920 
Officer Compensation   341,000    434,365    16,750    195,251 
Salaries and Related   -    196,250    -    2,500 
Depreciation and amortization   6,513    -    1,802    - 
Office Rent   5,796    1,870    3,294    405 
Impairment of inhouse software   -    -    -    - 
Non cash management fees   206,462    1,267,297    -    281,176 
Total operating expenses   1,164,706    2,937,437    218,876    762,912 
Loss from operations   (1,148,785)   (2,942,167)   (218,165)   (767,642)
Other Income (expense)                    
Other Income   -    690    -    (154)
Interest expense   (92,853)   (97,243)   (70,052)   (38,015)
Gain (Loss) on change of derivative liability   2,213,527    (3,168,598)   526,415    961,857 
Amortization of debt discount   -    (10,583)   -    - 
Amortization of issuance costs   (31,795)   (185,314)   -    (61,771)
Gain (loss) on settlement of derivative liabilities   -    -    -    - 
Legal settlement   -    -    -    - 
(Loss) Gain on settlement of notes payable   (176,222)   62,500    (176,096)   5,000 
Total other Income (expense)   1,912,657    (3,398,548)   280,267    866,917 
Income (loss) from investment in equity method investee   -    -    -    - 
NET INCOME (LOSS) from continuing operations   763,872    (6,340,715)   62,102    99,274 
NET INCOME (LOSS) from discontinued operations        -           
NET INCOME (LOSS)   763,872    (6,340,715)   62,102    99,274 
                     
Basic weighted average common shares outstanding   75,412,604    31,085,610    75,412,604    31,085,610 
Net Income (loss)  per common share: basic and diluted  $0.01   $(0.20)  $0.00    0.00 

 

The accompanying notes are an integral part of these audited consolidated financial statements 

 

F-2

 

 

RESONATE BLENDS, INC.

Consolidated Statement of Stockholders’ Equity (Deficit)

For the nine months period ended September 30, 2022

(unaudited)

 

                                         
   Preferred Stock Series A  

Preferred

stock - Series C

   Common Stock   APIC   Subscription Receivable   Accumulated   Total Stockholders’ 
Balance, December 31, 2021   -    -    2,000,000   $200    45,046,637   $4,504   $21,867,416   $-   $(25,974,051)  $(4,101,931)
Stock issuance in private placement   -    -              1,065,556    107    260,952    (261,059)   -    - 
Stock issuance for debt conversion   -    -              780,000    78    131,447    -    -    131,525 
Stock issuance for services   -    -              904,666    90    201,957    -    -    202,047 
Net income for the quarter   -    -    -    -                   -    490,040    490,040 
Balances March 31, 2022   -    -    2,000,000   $200    47,796,859   $4,779   $22,461,772   $(261,059)  $(25,484,011)  $(3,278,319)
Stock issuance for services   -    -              50,000    5    4,500    -    -    4,505 
Net income for the quarter   -    -    -    -              -    -    211,730    211,730 
Balance June 30, 2022   -    -    2,000,000   $200    47,846,859   $4,784   $22,466,272   $(261,059)  $(25,272,281)  $(3,062,084)
Stock issuance for services   -         -         25,000    3    2,246    -    -    2,249 
Stock issuance for debt conversion   -         -         21,969,316    2,197    1,973,944    -    -    1,976,141 
Stock issuance in private placement   -         -         5,571,429    557    243,360    -    -    243,917 
Net income for the quarter   -    -    -    -                   -    62,102    62,102 
Balance September 30, 2022   -    -    2,000,000   $200    75,412,604   $7,541   $24,685,822   $(261,059)  $(25,210,179)  $(777,675)

 

 

   Preferred Stock Series A  

Preferred

stock - Series C

   Common Stock       Subscription         
   Shares   Amount   Shares   Amount   Shares   Amount   APIC   Receivable   Deficit   Deficit 
Balance December 31, 2020   -    -    2,000,000   $200    29,769,627   $2,976   $20,101,480          -        $(21,100,995)  $(996,339)
Common stock issuance                       11,633,260    1,163    1,721,338              1,722,501 
Net income for the quarter   -    -    -    -                   -    (1,058,462)   (1,058,462)
Balance March 31, 2021   -    -    2,000,000   $200    41,402,887   $4,139   $21,822,818   $-   $(22,159,457)  $(332,300)
Common stock issuance                       2,868,025    288    582,920              583,208 
Net income for the quarter   -    -    -    -                   -    (5,381,529)   (5,381,529)
Balance June 30, 2021   -    -    2,000,000   $200    44,270,912   $4,427   $22,405,738   $-   $(27,540,986)  $(5,130,621)
Non-cash compensation                       716,554    72    328,632              328,704 
Net income for the quarter   -    -    -    -                   -    99,274    99,274 
Balance September 30, 2021   -    -    2,000,000   $200    44,987,466   $4,499   $22,734,370   $-   $(27,441,711)  $(4,702,643)

 

 The accompanying notes are an integral part of these audited consolidated financial statements

 

F-3

 

 

RESONATE BLENDS, INC.

Consolidated Statements of Cash Flows

For the nine months ended September 30, 2022 and 2021

(unaudited)

 

         
   September 30, 2022   September 30, 2021 
Cash Flows from Operating Activities          
Net Income (loss)  $763,872   $(6,340,715)
Net loss from discontinued operations          
Adjustments to reconcile          
Amortization and depreciation   6,513    10,583 
(Gain) Loss on derivative liability   (2,213,527)   3,106,826 
Non cash interest expense        16,142 
Stock subscription receivable   (261,059)     
Share professional fees/ compensation   206,462    82,473 
Share-based compensation   -    1,267,297 
Gain on settlement of Derivative liabilities   -    (62,500)
Changes in assets and liabilities          
Inventories   50,488    (234,998)
Prepaids        (23,485)
Advances to suppliers   (8,762)   (54,599)
Other receivables   (126,811)   - 
Accounts payable and accrued expenses   107,970    (57,091)
Derivative liabilities   -    - 
Due to Related party   (2,000)   (125,000)
Net cash used by operating activities   (1,476,854)   (2,415,066)
Net cash provided by  discontinued operations   -    - 
Net Cash Provided By Used In Operating Activities   (1,476,854)   (2,415,066)
Cash Flows from investing activities          
Purchase of fixed assets   -    (36,047)
Net cash used by investing activities   -    (36,047)
Cash Flows from Financing Activities          
Proceeds from subscription   349,981    1,367,115 
Proceeds from convertible notes (net)   1,388,800    1,865,000 
Payments on convertible notes payable   -    (504,793)
Net cash provided by financing activities   1,738,781    2,727,322 
Net increase in cash   261,927    276,209 
Cash, beginning of period   12,913    114,325 
Cash, end of period  $274,840   $390,534 
           
Supplemental disclosure of cash flow information          
Cash paid for interest  $-   $38,015 
Non-Cash investing and financing transactions   

-

    

-

 
Conversion of debt for common stock  $2,265,000   $306,858 

 

The accompanying notes are an integral part of these audited consolidated financial statements

 

F-4

 

 

RESONATE BLENDS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022

(UNAUDITED)

 

NOTE 1 – ORGANIZATION AND BUSINESS OPERATIONS

 

The Company

 

Resonate Blends, Inc. formerly Textmunication Holdings, Inc. (the “Company”) was incorporated on in October 1984 in the State of Georgia as Brock Control Systems. Founded by Richard T. Brock, the Company was in the sales automation market and an early developer of enterprise customer management systems. The Company went public at the end of March of 1993. In February of 1996, the Company changed its name to Brock International Inc., and in March of 1998, the Company again changed our name to Firstwave Technologies, Inc.

 

On October 25, 2019, the Company entered into a Membership Interest Purchase Agreement (the “Resonate Purchase Agreement”) with Resonate Blends, LLC, a California limited liability company (“Resonate”), and the members of Resonate. As a result of the transaction, Resonate became a wholly owned subsidiary of the Company. In accordance with the terms of the Purchase Agreement, at the closing an aggregate of 5% of the Company’s outstanding shares of common stock for a total of 665,072 shares were issued to the holders of Resonate in exchange for their membership interests of Resonate. These shares have anti-dilution protection. We have also agreed as part of the purchase price to issue: (ii) such number of shares of Series E Preferred Stock that will convert into 5% of the outstanding shares of common stock in the Company on a fully-diluted basis upon an annualized revenue run rate of Ten Million Dollars ($10,000,000.00) for any three (3) consecutive month trailing period; and (iii) such number of shares of Series E Preferred Stock that will convert into 5% of the outstanding shares of common stock in the Company on a fully-diluted basis upon the occurrence of the Company’s public market value reaching One Hundred Million US Dollars ($100,000,000). The shares in (ii) and (iii) shall have anti-dilution protections, except that this provision only applies for 2.5% of the outstanding shares acquired under each subsection.

 

Also, on October 25, 2019, the Company entered into a Membership Interest Purchase Agreement (the “Entourage Labs Purchase Agreement”) with Entourage Labs, LLC, a California limited liability company (“Entourage Labs”), and the members of Entourage Labs. As a result of the transaction, Entourage Labs became a wholly owned subsidiary of the Company. In accordance with the terms of the Purchase Agreement, at the closing an aggregate of 5% of the Company’s outstanding shares of common stock for a total of 665,072 shares were issued to the holders of Entourage Labs in exchange for their membership interests of Entourage Labs. These shares have anti-dilution protection. We have also agreed as part of the purchase price to issue: (ii) such number of shares of Series E Preferred Stock that will convert into 5% of the outstanding shares of common stock in the Company on a fully-diluted basis upon an annualized revenue run rate of Ten Million Dollars ($10,000,000.00) for any three (3) consecutive month trailing period; and (iii) such number of shares of Series E Preferred Stock that will convert into 5% of the outstanding shares of common stock in the Company on a fully-diluted basis upon the occurrence of the Company’s public market value reaching One Hundred Million US Dollars ($100,000,000). The shares in (ii) and (iii) shall have anti-dilution protections, except that this provision only applies for 2.5% of the outstanding shares acquired under each subsection.

 

In addition, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Conveyance Agreement”) with Mark S. Johnson and the Company’s 49% owned subsidiary, Aspire Consulting Group, LLC, a Virginia limited liability company. Pursuant to the Conveyance Agreement, the Company transferred all assets and business operations associated with its IT consulting solutions, including all of the capital stock of Aspire Consulting, to Mr. Johnson. In exchange, Mr. Johnson agreed to cancel 20,000 shares of common stock in the Company and to assume and cancel all liabilities relating to the Company’s former business.

 

The Company entered into Employment Agreements with the following persons: (i) Geoffrey Selzer as Chief Executive Officer (CEO) of the Company with an annual salary of $180,000; and (ii) Pamela Kerwin as Chief Operating Officer (COO) of the Company with an annual salary of $120,000. Both are eligible for salary increases upon milestone achievements and other benefits. The Employment Agreement for the CEO has a term of 2 years and can’t be terminated without cause. Severance of six (6) weeks is available for termination of the COO without cause before one-year of service and eight (8) weeks after one-year of service.

 

On December 16, 2019 the Company filed Articles of Merger with the Secretary of State of Nevada in order to effectuate a merger with its wholly owned subsidiary; Resonate Blends, Inc. Shareholder approval was not required under Section 92A.180 of the Nevada Revised Statutes. As part of the merger, the Company’s board of directors authorized a change in our name to “Resonate Blends, Inc.” and the Company’s Articles of Incorporation have been amended to reflect this name change.

 

On January 20, 2020, Wais Asefi resigned as Chairman and as a member of our Board of Directors. Mr. Asefi’s resignation is in support of Resonate Blends strategic direction of becoming a pure play cannabis company. The Company does not believe that Mr. Asefi has any disagreements on matters relating to our operations, policies or practices. Also, on January 20, 2020, our Board of Directors appointed Geoffrey Selzer as our Chairman.

 

In connection with the name change, the Company’s symbol was changed to “KOAN” that more resembles the Company’s new business focus.

 

On May 22, 2020, Resonate Blends, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “SPA”) with Wais Asefi, Nick Miniello, Juleon Asefi, and Curt Byers (collectively, the “Asefi Group”) to sell to the Asefi Group its subsidiary, Textmunication, Inc., a California corporation (“Textmunication”). Textmunication operates the Company’s SMS business activities. The Company will retain its cannabis operations based in Calabasas, California.

 

The consideration for the sale of Textmunication consists of the cancellation by the Asefi Group of 4,822,029 shares of common stock (the “Shares”) of the Company. The Shares have a market value of $337,542, based on our last sales price of $0.07 per share as of May 26, 2020. Upon the cancellation of the Shares, the Company agreed to execute a general release in favor of Mr. Asefi.

 

Also on May 22, 2020, the Company entered into a Separation and Release Agreement (the “Separation Agreement”) with Wais Asefi. Pursuant to the Separation Agreement, Mr. Asefi agreed to separate from all officer positions and as a director of the Company and to further accept the payment of $200,000 from the Company’s future fundraising as consideration of all debts outstanding under Mr. Asefi’s employment agreement with the Company. Mr. Asefi further agreed to cancel his 4,000,000 shares of Series A Preferred Stock and to transfer his 2,000,000 shares of Series C Preferred Stock to Geoffrey Selzer, the Company’s current CEO and Director. Mr. Asefi further released the Company of all claims.

 

Also on May 22, 2020, Mr. Selzer signed a Voting Agreement and agreed to vote his newly acquired 2,000,000 shares of Series C Preferred Stock in favor of the sale of Textmunication to the Asefi Group.

 

On July 20, 2020, the parties closed on the transactions contained in the SPA. The Asefi Group cancelled 4,822,029 shares of common stock (the “Shares”) of the Company. The Shares have a market value of $332,842, based on our last sales price of $0.07 per share as of May 26, 2020. The Company also executed a general release in favor of Mr. Asefi.

 

F-5

 

 

Basis of Presentation

 

The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted.

 

Going concern

 

These consolidated financial statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of September 30, 2022, the Company has an accumulated deficit of $25,210,179. The company’s ability to continue as a going concern is contingent upon the successful completion of additional financing arrangements and its ability to achieve and maintain profitable operations. While the Company is expanding its best efforts to achieve the above plans, there is no assurance that any such activity will generate funds that will be available for operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these financial statements. These consolidated financial statements do not include any adjustments that might arise from this uncertainty.

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Cash

 

The Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents.

 

The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits. However, as of September 30, 2022, the company balances were above the federally insured limit by approximately $24,840. Management is making certain arrangements to mitigate this risk during the next quarter.

 

Revenue Recognition

 

The Company did have any revenues from continuing operations for the periods presented. The Company’s policy is that revenues will be recognized when control of the product is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those services.

 

Fair Value of Financial Instruments

 

The carrying amounts reflected in the balance sheets for cash, accounts payable and accrued expenses approximate the respective fair values due to the short maturities of these items.

 

As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

 

F-6

 

 

The three levels of the fair value hierarchy are described below:

 

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

 

Level 2: Quoted prices in markets that are not active, or inputs that is observable, either directly or indirectly, for substantially the full term of the asset or liability;

 

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

 

Financial assets and liabilities measured at fair value on a recurring basis are summarized below for the quarter ended September 30, 2022 and year ended December 31, 2021.

 

                     
As of September 30, 2022  Level 1   Level 2   Level 3   Total 
Liabilities                    
Derivative Liabilities   -    -    72,487    72,487 

 

                     
As of December 31, 2021  Level 1   Level 2   Level 3   Total 
Liabilities                    
Derivative Liabilities   -    -    2,286,014    2,286,014 

 

Net income (loss) per Common Share

 

Basic net income (loss) per share is computed by dividing the net loss attributable to the common stockholders by the weighted average number of shares of common stock outstanding during the period. Fully diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.

 

Property and equipment

 

Property and equipment are stated at cost, less accumulated depreciation provided on the straight-line method over the estimated useful lives of the assets, which range from three to seven years. Expenditures for renewals or betterments are capitalized, and repairs and maintenance are charged to expense as incurred the cost and accumulated depreciation of assets sold or otherwise disposed of are removed from the accounts, and any gain or loss thereon is reflected in operations. Company policies capitalize property and equipment for cost over $1,000, asset acquired under $1,000 are charge to operations.

 

Income Taxes

 

Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. Because the Company has no net income, the tax benefit of the accumulated net loss has been fully offset by an equal valuation allowance.

 

F-7

 

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Stock-Based Compensation

 

The Company accounts for employee stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation – Stock Compensation which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values. The fair value of the equity instrument is charged directly to compensation expense and credited to additional paid-in capital over the period during which services are rendered.

 

The Company follows ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options and warrants issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option or warrant, whichever can be more clearly determined. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital over the period during which services are rendered.

 

NOTE 3 – RELATED PARTY TRANSACTIONS

 

On May 22, 2020, the Company entered into a Separation and Release Agreement (the “Separation Agreement”) with Wais Asefi. Pursuant to the Separation Agreement, Mr. Asefi agreed to separate from all officer positions and as a director of the Company and to further accept the payment of $200,000 from the Company’s future fundraising as consideration of all debts outstanding under Mr. Asefi’s employment agreement with the Company. Mr. Asefi further agreed to cancel his 4,000,000 shares of Series A Preferred Stock and to transfer his 2,000,000 shares of Series C Preferred Stock to Geoffrey Selzer, the Company’s current CEO and Director. Mr. Asefi further released the Company of all claims.

 

On May 22, 2020, the 4,000,000 shares of Series A Preferred Stock were returned to the Company’s transfer agent and cancelled and on May 22, 2020 the 2,000,000 shares of Series C Preferred Stock were transferred to Mr. Selzer. The parties to the Separation Agreement agreed to a payment schedule of $200,000 based on future monies raised by the Company - and not on a specific date – as follows:

 

  ● $12,500 when the initial $250,000 is raised by the Company;
  ● $12,500 when a total of $500,000 is raised by the Company;
  ● $10,000 when a total of $750,000 is raised by the Company;
  ● $35,000 when a total of $1,750,000 is raised by the Company;
  ● $35,000 when a total of $2,750,000 is raised by the Company;
  ● $35,000 when a total of $3,750,000 is raised by the Company;
  ● $35,000 when a total of $4,750,000 is raised by the Company; and
  ● $25,000 when a total of $5,750,000 is raised by the Company.

 

On May 13, 2021, we amended the Separation Agreement to state the parties desire to reduce the total amount payable to Wais Asefi from $200,000 USD to $142,500 USD. In addition to the earlier payments made to Mr. Asefi, a payment of $40,000 was made on May 14, 2021 and another payment on June 27, 2021 for $40,000. The final payment was made on August 11, 2021 for $25,000 and settled this agreement in full. Further under the amendment, Mr. Asefi nominated Textmunication, Inc., our prior subsidiary, as the recipient of the funds due under the Separation Agreement.

 

The outstanding balances as of September 30, 2022 and December 31, 2021 are $43,000 and $45,000 respectively. The remaining balance is due to Mr. Selzer, CEO of Resonate, as he provided a loan to the Company.

 

F-8

 

 

NOTE 4 - CONVERTIBLE NOTE PAYABLE

 

Convertible notes payable consists of the following as of September 30, 2022 and December 31, 2021:

 

           
   September30, 2022   December 31, 2021 
Convertible notes face value  $988,800   $1,865,000 
Less: Discounts   -    - 
Less: Debt issuance cost   -    - 
Net convertible notes  $988,800   $1,865,000 

 

The convertible notes as of September 30, 2022 are 8% Unsecured Convertible Promissory Notes (“Notes”) from various accredited investors issued from January 1, 2021 to September 30, 2022. All notes have an automatic conversion into equity on the maturity date, which was July 3, 2022, or if a Qualified Financing (QF) of $5,000,000 is achieved, whichever occurs first. The maturity date pricing is $0.10. A QF converts into equity at the lesser of $1.00 or 75% of the average selling price of the aggregate offering. The outstanding balance as of September 30, 2022 for this Unsecured Convertible Promissory Notes amounts to $200,000.. On January 2, 2022, Certain Noteholders elected to convert collectively $150,000 of the Notes into equity at $0.10 to reduce the outstanding principal.

 

On January 28, 2022, we entered into Securities Purchase Agreements (the “Purchase Agreements”) with two accredited investors, pursuant to which we issued and sold to the investors two convertible promissory notes, dated January 28, 2022, each in the principal amount of $275,000 for an aggregate principal amount of $550,000. We received $500,000 from the Notes after applying the original issue discount to the Notes.

 

The Purchase Agreements allow for additional notes to be issued to investors up to $750,000. On February 4, 2022, we issued and sold to two accredited investors (the “Investors”) convertible promissory notes in the principal amount of $55,000 under a Securities Purchase Agreement of the same date. We received $150,000 from the Notes after applying the original issue discount to the Notes.

 

On March 3, 2022, we issued and sold to an accredited investor a convertible promissory note the principal amount of $55,000 under a Securities Purchase Agreement of the same date. We received $50,000 from the Note after applying the original issue discount to the Note.

 

The maturity date for repayment of the Notes is nine months from issuance and the Notes bear interest at 10% per annum. We may prepay the Notes provided that we shall make payment to the investors of an amount in cash equal to the sum of: the then outstanding principal amount of this Notes, plus interest on the unpaid principal amount of the Notes, plus any Default Interest on the amounts, plus any amounts owed to the Investor pursuant to the Purchase Agreement.

 

All principal and accrued interest on the Notes are convertible into shares of our common stock. The conversion price shall equal a fixed price of $0.15 per share or, at the option of the Investor in the event that we fail to complete a Qualified Offering before the five (5) month anniversary of the issue date, the Registration Conversion Price. The “Registration Conversion Price” shall mean 75% multiplied by the volume weighted average of the Common Stock during the twenty (20) Trading Day period ending on the latest complete Trading Day prior to the Conversion Date. The Investors shall be entitled to add to the principal amount of the Note $750.00 for each conversion to cover investor’s deposit fees associated with each Notice of Conversion. “Qualified Offering” means any offer and sale by us of an original issuance of equity securities, comprised of either Common Stock or preferred stock of the Company, in a single transaction to investors pursuant to which at least an aggregate of $2,000,000.00 gross proceeds are received by the Company.

 

In the event that by the five (5) month anniversary of the issue date a Qualified Offering (as defined above) has not occurred, then we shall file with the SEC a registration statement on Form S-1 covering the resale of the maximum number of Registrable Securities, defined as the Commitment Shares, Conversion Shares and Warrant Shares.

 

F-9

 

 

In connection with the investment, we issued Commitment Shares to the Investors in the amount of 650,000 shares collectively and we also issued a warrant (the “Warrant”) to the Investors to purchase 812,500 shares collectively of our common stock at an exercise price of $0.40 per share. In the event that there is no effective registration statement five months from the issue date registering the shares underlying the Warrant, then the Investors may exercise the Warrant using a cashless feature.

 

The Securities Purchase Agreement contain a most favored nation provision that allows the Investor to claim any lower price from any future securities six months after this closing and a blocker on issuing variable rate investments.

 

On June 27, 2022, we issued and sold to an accredited investor a convertible promissory note the principal amount of $138,800 under a Securities Purchase Agreement of the same date. We received $128,500 from the Note after applying the original issue discount to the Note.

 

The Notes are convertible into shares of common stock, $0.0001 par value per share, of the Company upon the terms and subject to the limitations and conditions set forth in such Note. On the Closing Date (i) the Buyer shall pay the purchase price for the Note to be issued and sold to it at the Closing (as defined below) (the “Purchase Price”) by wire transfer of immediately available funds to the Company, in accordance with the Company’s written wiring instructions, against delivery of the Note in the principal amount equal to the Purchase Price as is set forth immediately below the Buyer’s name on the signature pages hereto, and (ii) the Company shall deliver such duly executed Note on behalf of the Company, to the Buyer, against delivery of such Purchase Price .

 

Finally, on September 8, 2022, we issued and sold a convertible promissory note to AJB Capital Investments LLC for a principal amount of $600,000, together with guaranteed interest of 12% per year calendar from the date hereof. All Principal and Interest owing hereunder, along with any and all other amounts, shall be due and owing on the Maturity Date March 8, 2023.

 

The Maturity Date may be extended at the sole discretion of the Borrower up to six (6) months following the date of the original Maturity Date hereunder. In the event that the Maturity Date is extended, the interest rate shall equal fifteen percent (15%) per annum for any period following the original Maturity Date, payable monthly.

 

We received $540,000 from the Note after applying the original issue discount to the Note.

 

In connection with the investment, we issued Commitment Shares to the Investors in the amount of 5,571,429 shares collectively. A total of 3,000,000 of those shares can be returned to treasury if the Note is paid off within six (6) months.

 

The nine months ended September 2022 and 2021 interest accrued for the convertible notes payable at $92,853 and $97,243,respectively.

 

NOTE 5 – COMMITMENTS AND CONTINGENCIES

 

Office Lease

 

On October 16, 2019, the Company signed a lease agreement that expires on thirty days’ notice. Rent expense was approximately $5,796 and $1,870 for the nine-months period ended September 30, 2022 and 2021, respectively.

 

Executive Employment Agreement

 

On October 25, 2019, the Company entered into Employment Agreements with the following persons: (i) Geoffrey Selzer as Chief Executive Officer (CEO) of the Company with an annual salary of $180,000; (ii) Pamela Kerwin as Chief Operating Officer (COO) of the Company with an annual salary of $120,000: and David Thielen as Chief Investment Officer (CIO) with an annual salary of $120,000. All are eligible for salary increases upon milestone achievements and other benefits. The Employment Agreement for the CEO has a term of 2 years and can’t be terminated without cause. Severance of six (6) weeks is available for termination of the COO and CIO without cause before one-year of service and eight (8) weeks after one-year of service.

 

F-10

 

 

NOTE 6 – STOCKHOLDERS’ EQUITY

 

During the third quarter of 2022 the company issued a total of 27,565,745 shares of common stock to vendors for compensation, services rendered and commitment shares. The fair market value of the shares issued accounted as expenses as follows:

 

 

      
Professional Fees  $2,249 
Commitment shares   243,917 
Convertible promissory notes   1,976,141 
Total  $2,222,307 

 

NOTE 7 – DISCONTINUED OPERATIONS

 

On July 20, 2020, the Company finalized a Stock Purchase Agreement (the “SPA”) with Wais Asefi, Nick Miniello, Juleon Asefi, and Curt Byers (collectively, the “Asefi Group”) to sell to the Asefi Group its subsidiary, Textmunication, Inc., a California corporation (“Textmunication”). Textmunication operates the Company’s SMS business activities. The Company retained its cannabis operations based in Calabasas, California. The Company has accounted for this spinout as a discontinued operation and retroactively reclassified all previously presented financial information. The following summarizes the results of operations for Textmunication, Inc. for the three months ended June 30, 2020

 

      
   2020 
Revenues  $305,590 
Cost of Revenues   (90,559)
Operating expenses   (347,565)
Loss from operations of discontinued operations   (132,534)

 

NOTE 8 – SUBSEQUENT EVENTS

 

In accordance with FASB ASC 855-10, Subsequent Events, the Company has analyzed its operations subsequent to September 30, 2022 to the date these financial statements were issued and has determined that it does not have any material subsequent events to disclose in these consolidated financial statements.

 

F-11

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-Looking Statements

 

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include but are not limited to changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

 

Company Overview

 

On October 25, 2019, the Company announced its entry into the cannabis industry by acquiring Resonate Blends LLC (“Resonate Blends”), a California-based cannabis wellness lifestyle product company built on a proprietary system of experiential targets. Resonate Blends is building a value-added, brand-focused cannabis organization offering premium brands of consistent quality. The Company also acquired Entourage Labs LLC (“Entourage Labs”), a sister company of Resonate Blends. Entourage Labs is the Intellectual Property (IP) subsidiary of Resonate Blends.

 

Based in Calabasas, California, the Company is a cannabis holding company centered on value-added holistic Wellness and Lifestyle brands. The Company’s strategy is to ignite future growth by building a purpose-driven portfolio of innovative, trusted national brands, emerging brands, research organizations, and a variety of retail channels. The Company’s focus is finding mutual value between product and consumer by optimizing quality, supply chain resources and financial performance. The Company offers a family of premium cannabis-based products of consistent quality based on unique formations calibrated to Resonate Blends effects system in what the Company believes is the industry gold standard in user experience.

 

Resonate believes the greatest long-term value creation in the cannabis industry will be in the establishment of high quality and consistent consumer brands. Resonate hopes to become a national leader through its vision in creating a family of brands designed specifically to deliver reliable, effective and beneficial experiences.

 

Resonate is committed to helping people live the life they love, but they do not make the medicinal vs. recreational distinction. This is a temporary legal separation in some states that should soon cease to exist. The Company believes in wellness for the whole person, especially people with insomnia, pain or anxiety who also want to enjoy friends, concerts and have satisfying intimate experiences. Resonate is designing experiences which should improve all areas of ones’ life.

 

3

 

 

To accomplish this, Resonate is Mastering the Art of Experience. This is the Company’s mission. By integrating science, technology, education, branding, marketing, sales and delivery - with every customer interaction they aim to provide exceptional experiences. Cannabis has a broad range of unique characteristics, and they are dedicated to harnessing and amplifying those characteristics to support healthy empowered and engaged lifestyles. From product development through customer communication, they prefect and demystify cannabis bringing innovative products to an increasingly sophisticated market. Resonate Blends has a strong social mission and the Resonate team is building a successful business by focusing its knowledge, skill and energy on creating wellness-lifestyle products which will improve community by helping individuals live more satisfying, meaningful and connected lives. The need for these products currently is crucial.

 

To communicate the breadth of wellness products that Resonate is developing, the Company created The Resonate System. The Resonate System graphically represents a spectrum of wellness products based on cannabis scaffolding. This system helps users easily select which product they want. Products based on The Resonate System deliver relaxation, freedom from pain and anxiety, boosts in focus and creativity, sensuality, human connection and joy. Koan products are formulated around a system of interconnected experience targets that will allow you to know exactly what to expect when using them.

 

While respecting and honoring the natural power of plant medicine, Resonate also employs advanced science, leading technology and a deep understanding of how various cannabis compounds, when working in the body, simultaneously can create unique effects and benefits (referred to as the “Entourage Effect”). Product developers blend cannabinoids and terpenes to formulate products with specific, controllable and repeatable beneficial effects. Through innovation, experimentation, testing and an iterative product development strategy, the Koan team has unlocked new plant constituent combinations resulting in unique, enjoyable and extremely effective wellness products unlike anything else in the marketplace. Resonate has filed a provisional patent for protection of these formulations and products in the future.

 

Koan, the Resonate Blends product family, is based around a comprehensive system of interconnected experience targets that allow people to select the products that best fit their lifestyle and health objectives. Koan products are dedicated to the efficacy and precision of functional experience targets across a broad range of product categories.

 

Resonate’s initial products are a completely unique class of products called Cordials. These blends offer a wide range of experiences not currently available in the cannabis market. Cordials are water-soluble and use nano-emulsification technology to allow for quick onset and a sustained and nuanced experience. Single dose, healthful, subtle in taste, cordials are an ideal way for people to intentionally improve their well-being. They can be shipped directly or substituted for alcohol as a cocktail mixer. A significant competitive advantage is that the Cordials allow users to select both the experience they want and the beverage they choose to enjoy them in.

 

Resonate’s Cordials have been developed in partnership with an award-winning advanced infusion technology partner and were launched to the retail channel in late Q2 of 2021. The company is now offering seven unique formulations including the newly released Sleep Cordial available as of September 29, 2022. The Sleep Cordial has been thoroughly tested and is now available in “Single” samples and in cost effective 100 ml, 10 serving multi-serve bottles. Koan Cordials now come in: Calm, Create, Delight, Love, Play, Wonder and Sleep experience-targeted blends providing consumers a choice on how they want to feel.

 

The Cordials were awarded the Golden Leaf Award as “Best New Brand of 2021” at the “Luxury Meets Cannabis Conference” held in New York City in December. Resonate also won a Cannabis Clio Award for “Brand Design” in 2021.

 

Resonate has formalized contracts with logistical, sales and marketing partners to build a digital native strategy supporting Direct-to-Consumer (D2C) sales. The D2C sales platform launched in October 2021 and now allows California consumers the ability to order on-line and have the Cordials home delivered in most metro areas within four hours. Based on customer demand, the Company offers a “Singles” option for the Cordials which are now available. In response to customer requests, the company is now offering five popular blends in 10-serving bottles, also known as “multi-serve” bottles, that provide a lower cost per serving and allow users to customize their servings to their personal preference. In addition, the company is also offering a 4-pack that also lowers the cost per serving while preserving the convenience and portability of the discrete smaller bottles.

 

4

 

 

The Company offers market support to select premium California dispensaries both in person and thorough the Leaf.VIP budtender training program. The Company expects that building its brand online will complement retail sales by increasing customer awareness and creating “pull-through” at brick-and-mortar facilities. The social media strategy was brought in-house during Q1 to both reduce overall costs and control the messaging to the appropriate audience for the Cordials.

 

Resonate recently hired an internal sales manager to oversee all sales efforts in Southern California and expects to hire a sales manager for Northern California in the near future. The Company implemented an in-house sales strategy in Q1 2022 to maximize both the dispensary outreach and budtender education – and to increase D2C sales platform activity. The Company has added several new retail partners in 2022 to include Atrium, Cornerstone Wellness, 99 High Tide, Artist Tree, Canni Delivery and Rose Mary Jane. The Cordials are now featured at West Hollywood’s The Artist Tree Studio Cannabis Lounge where music performers will be providing the entertainment events throughout the summer. The Studio Cannabis Lounge in West Hollywood is the only one of its kind in the United States and this partnership should provide users an interactive experience unavailable elsewhere. Rose Mary Jane Cannabis Lounge in Oakland also added the Cordials to its menu on September 24, 2022. The Company is placing a major focus on cannabis lounges throughout California to enhance its marketing and sales efforts.

 

With the new in-house sales strategy in place, new wellness dispensaries are expected to grow throughout 2022 Wellness dispensaries are the main target due to the demographics of the consumer and the thorough educational process these dispensaries offer to buyers in their stores. Multi-state expansion through licensing arrangements with the Cordials is also being planned. Several retailers and leading brands in multiple states have reached out to Resonate requesting the Cordials to be stocked in their dispensaries. The Company is currently evaluating where and when to open new states outside of California.

 

We are in negotiations with Chemistry, Inc. (“Chemistry”), a California corporation, to acquire the company pending execution of definitive agreements, obtaining the required corporate approvals and other matters. We are no longer pursuing Iron Summit Distribution, Inc., as was announced on September 20 through a Press Release, but are instead focused on an anticipated closing of Chemistry in Q4 2022.

 

The principal executive office is located at 26565 Agoura Road, Suite 200, Calabasas, CA 91302. The executive telephone number is (571) 888-0009.

 

Results of Operation for Three and Nine Months period Ended September 30, 2022 and 2021

 

Revenues

 

We have generated $10,429 and $40,917 in sales for the three and nine months period ended September 30, 2022, respectively, as compared with $7,574 in sales for the three months and nine months period ended September 30, 2021 on our current product line. We launched our first line of seven Cordial products in California and we have started to generate revenues from the sale of these products.

 

We anticipate increased revenues on our seven Cordials including our newly launched Sleep Cordial, discussed above, for the rest of 2022. In Q3 2022, we rolled out a new packaging configuration for our Cordials: to include a one-pack, a 4-pack to replace the 3-pack and a multi-dose bottle which is expected to bring the cost per dose down considerably. We also plan on launching a new line of edibles in late 2022, which we hope will contribute to increasing our revenues. As we have just launched our products, however, it may take some time for the markets to react, gain traction and result in brand awareness among our customers. There can be no assurances, however, that customers will positively react to our products.

 

5

 

 

Gross Profit

 

We accrued $9,718 and $24,996 in cost of revenues for the three and nine months period ended September 30, 2022, respectively, resulting in a gross profit of $711 and $15,921 for the three and nine months period ended September 30, 2022, respectively. We have had little historical data to compare our margins for the sale of our new products, which were introduced into the retail channel in late Q2 of 2021. We accrued $12,304 in cost of revenues for the three months ended September 30, 2021, resulting in a gross loss of $4,730 for the three months ended September 30, 2021. Our gross margin, which is the difference between our revenues and our cost of revenues, is expected to increase in future quarters as we work to increase our efficiency and lessen costs. In addition, our gross margin percentage, which was 6.82% and 38.91% for the three and nine months period ended September 30, 2022, respectively, and we hope will stabilize in the 35% to 43% range as we implement cost saving measures and roll out new products to increase sales for the balance of 2022. We are also implementing new packaging configurations which we expect to stabilize our overall gross margin.

 

Operating Expenses

 

Our operating expenses were $218,876 and $1,164,706 for the three and nine months period ended September 30, 2022, respectively, as compared with $762,912 and $2,937,437 for the three and nine months period ended September 30, 2021, respectively.

 

The main drivers for the overall decrease in operating expenses in Q3 2022 were the reduction of Legal, Professional Fees and Salaries as well as a significant decrease in non-cash management fees.

 

Not having these non-cash management and broker fees would reduce our operating expenses by $0 and $206,462 for the three and nine months period ended September 30, 2022, respectively. Our continued focus on sales, advertising, marketing and new product development costs to support our planned growth is expected to increase throughout 2022.

 

We spent $129,316 and $104,957 less on advertising for the three and nine months period ended September 30, 2022, respectively, than for the same periods in 2021. We spent more on advertising for the nine-month ended September 30, 2021 particularly the first quarter to introduce our Koan Cordials to the California retail channel, perform Search Engine Optimization (SEO), conduct Programmatic advertising, hire a professional agency to promote our Cordials on social media channels and other general advertising methods. We believe our advertising efforts will pay dividends for the rest of 2022 and into 2023 as the awareness groundwork has been established to educate the market on our family of Cordial formulations.

 

Professional fees decreased by $27,951 and $381,618 for the three and nine months period ended September 30, 2022, respectively, over for the same periods in 2021. Our professional fees were less for this period compared to last period, but we expect that professional fees will increase in 2022 as we continue to ramp up operations.

 

General and administrative expenses increased by $70,717 and $53,855 for the three and nine months period ended September 30, 2022, respectively, over for the same periods in 2021. The increased expenses resulted from establishing our internal sales team, attending strategic trade shows and bringing on consultants and financial analysts to assist in analyzing our acquisition strategy. We expect general and administrative expenses to remain fairly constant throughout 2022, but they could increase significantly if we acquire new companies as part of our overall corporate strategy.

 

We also expect that our operating expenses will increase in 2022 over 2021 as we roll out new products along with our existing products, and the increased expenses associated with operations.

 

Other Income/Expenses

 

We had other income of $280,267 and $1,912,657 for the three and nine months period ended September 30, 2022, respectively, compared with other income of $866,917 and other expense of $3,398,548, respectively, for the same periods ended September 30, 2021, respectively.

 

The main reason for our other income in 2022 was the gain on revaluation of derivative liabilities. The main reason for our other expenses in 2021 was the loss on revaluation of derivative liabilities.

 

6

 

 

Net Income/Loss

 

We had net income of $62,102 and $763,872 for the three and nine months period ended September 30, 2022, as compared with net income of $99,274 and a net loss of $6,340,715 for the three and nine months period ended September 30, 2021, respectively.

 

Liquidity and Capital Resources

 

As of September 30, 2022, we had total current assets of $616,531 consisting of $274,840 in cash, $19,592 in advances to suppliers, $126,811 in other receivable and $195,288 in inventories. Our total current liabilities as of September 30, 2022 were $1,419,130. We had a working capital deficit of $802,599 as of September 30, 2022 compared with a working capital deficit of $3,088,810 as of June 30, 2022 and $4,133,368 as of December 31, 2021.

 

Cash Flows from Operating Activities

 

Operating activities used $1,476,854 in cash for the nine months period ended September 30, 2022, compared with cash used of $ 2,415,066 for the nine months period ended September 30, 2021. Our negative operating cash flow for the nine months period ended September 30, 2022 was largely the result of our unrealized gain on derivative liability of $2,213,527, offset by our net income of $763,872. Our negative operating cash flow for the nine months period ended September 30, 2021 was largely the result of our net loss of $6,340,715, offset by share based compensation of $1,267,297 and the unrealized loss on derivative liability of $3,106,826.

 

Cash Flows from Investing Activities

 

Investing activities used $0 in cash for the nine months period ended September 30, 2022, as compared with $36,047 to purchase computer equipment for the nine months period ended September 30, 2021.

 

Cash Flows from Financing Activities

 

Cash flows provided by financing activities during the nine months period ended September 30, 2022 amounted to $1,738,781, compared with cash flows provided by financing activities of $2,727,322 for the nine months period ended September 30, 2021. Our positive cash flows for the nine months period ended September 30, 2022 consisted of proceeds from issuance of common stock of $349,981 and proceeds from Convertible notes payable of $1,388,800. Our positive cash flows for the nine months period ended September 30, 2021 consisted of proceeds from issuance of common stock of $1,367,115, proceeds from Convertible notes payable of $1,865,000, offset by payments of notes payable of $504,793.

 

The features of the debt instruments and payables concerning our financing activities are detailed in the footnotes to our financial statements.

 

We are dependent on investment capital to continue our survival. We have raised money through convertible debt, almost always on unfavorable terms. There is no guarantee that these small convertible loans will be available to us in the future or on terms acceptable to us.

 

We also plan to raise money in the sale of our equity and debt securities. There can be no assurance of funds from these efforts or that any other type of additional financing will be available to us on acceptable terms, or at all.

 

Going Concern

 

As of September 30, 2022, we have an accumulated deficit of $25,210,179. Our ability to continue as a going concern is contingent upon the successful completion of additional financing arrangements and our ability to achieve and maintain profitable operations. While we are expanding our best efforts to achieve the above plans, there is no assurance that any such activity will generate funds that will be available for operations. These conditions raise substantial doubt about our ability to continue as a going concern. These financial statements do not include any adjustments that might arise from this uncertainty.

 

7

 

 

Off Balance Sheet Arrangements

 

As of September 30, 2022, there were no off-balance sheet arrangements.

 

Critical Accounting Policies

 

In December 2001, the SEC requested that all registrants list their most “critical accounting polices” in the Management Discussion and Analysis. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a company’s financial condition and results, and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Our critical accounting policies are disclosed in Note 2 of our audited financial statements included in the Form 10-K filed with the Securities and Exchange Commission.

 

Recent Accounting Pronouncements

 

No new accounting pronouncements issued or effective during the fiscal year has had or is expected to have a material impact on the financial statements.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

A smaller reporting company is not required to provide the information required by this Item.

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

We conducted an evaluation, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of September 30, 2022, to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities Exchange Commission’s rules and forms, including to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of September 30, 2022, our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses identified and described below.

 

Our principal executive officers do not expect that our disclosure controls or internal controls will prevent all error and all fraud. Although our disclosure controls and procedures were designed to provide reasonable assurance of achieving their objectives and our principal executive officers have determined that our disclosure controls and procedures are effective at doing so, a control system, no matter how well conceived and operated, can provide only reasonable, not absolute assurance that the objectives of the system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented if there exists in an individual a desire to do so. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

8

 

 

Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Management identified the following three material weaknesses that have caused management to conclude that, as of September 30, 2022, our disclosure controls and procedures, and our internal control over financial reporting, were not effective at the reasonable assurance level:

 

1. We do not have written documentation of our internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act as of the period ending September 30, 2022. Management evaluated the impact of our failure to have written documentation of our internal controls and procedures on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.
2. We do not have sufficient segregation of duties within accounting functions, which is a basic internal control. Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. Management evaluated the impact of our failure to have segregation of duties on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.
3. Effective controls over the control environment were not maintained. Specifically, a formally adopted written code of business conduct and ethics that governs our employees, officers, and directors was not in place. Additionally, management has not developed and effectively communicated to employees its accounting policies and procedures. This has resulted in inconsistent practices. Further, our Board of Directors does not currently have any independent members and no director qualifies as an audit committee financial expert as defined in Item 407(d)(5)(ii) of Regulation S-K. Since these entity level programs have a pervasive effect across the organization, management has determined that these circumstances constitute a material weakness.

 

To address these material weaknesses, management performed additional analyses and other procedures to ensure that the financial statements included herein fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented. Accordingly, we believe that the financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented.

 

To remediate the material weakness in our documentation, evaluation and testing of internal controls we plan to engage a third-party firm to assist us in remedying this material weakness once resources become available.

 

We intend to remedy our material weakness with regard to insufficient segregation of duties by hiring additional employees in order to segregate duties in a manner that establishes effective internal controls once resources become available.

 

Changes in Internal Control over Financial Reporting

 

No change in our system of internal control over financial reporting occurred during the period covered by this report, the period ended September 30, 2022, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

9

 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We are not a party to any pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

 

Item 1A: Risk Factors

 

See risk factors included in our Annual Report on Form 10-K/A for the year ended December 31, 2021 filed on April 19, 2022.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

The information set forth below relates to our issuances of securities without registration under the Securities Act of 1933.

 

During the third quarter of 2022, we issued a total of 27,565,745 shares of common stock to vendors for compensation, services rendered and commitment shares.

 

These securities were issued pursuant to Section 4(2) of the Securities Act and/or Rule 506 promulgated thereunder. The holders represented their intention to acquire the securities for investment only and not with a view towards distribution. The investors were given adequate information about us to make an informed investment decision. We did not engage in any general solicitation or advertising. We directed our transfer agent to issue the stock certificates with the appropriate restrictive legend affixed to the restricted stock.

 

Item 3. Defaults upon Senior Securities

 

None

 

Item 4. Mine Safety Disclosures

 

None

 

Item 5. Other Information

 

None

 

Item 6. Exhibits

 

Exhibit Number   Description of Exhibit
     
3.1   Certificate of Amendment dated July 20, 2020
31.1   Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2   Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101**   The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 formatted in Extensible Business Reporting Language (XBRL).
     
    **Provided herewith

 

10

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Resonate Blends, Inc.  
     
Date: November 21, 2022  
     
By: /s/ Geoffrey Selzer  
  Geoffrey Selzer  
Title:

President, Chief Executive Officer, Principal

Executive Officer, Principal Financial Officer,

Principal Accounting Officer and Director

  

 

11
Resonate Blends (PK) (USOTC:KOAN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Resonate Blends (PK) Charts.
Resonate Blends (PK) (USOTC:KOAN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Resonate Blends (PK) Charts.